Transcription_NN
factor_NN
activation_NN
in_IN
lymphokine_NN
activated_VBD
killer_NN
cells_NNS
and_CC
lymphocytes_NNS
from_IN
patients_NNS
receiving_VBG
IL-2_NN
immunotherapy_NN
._.

Administration_NN
of_IN
the_DT
cytokine_NN
interleukin-2_NN
-LRB-_-LRB-
IL-2_NN
-RRB-_-RRB-
can_MD
result_VB
in_IN
therapeutic_JJ
benefits_NNS
for_IN
individuals_NNS
with_IN
renal_JJ
cell_NN
carcinoma_NN
and_CC
melanoma_NN
._.

Here_RB
we_PRP
report_VBP
an_DT
analysis_NN
of_IN
the_DT
transcription_NN
factor_NN
families_NNS
AP-1_NN
,_,
Sp1_NN
,_,
NF-kappaB_NN
,_,
and_CC
signal_NN
transducers_NNS
and_CC
activators_NNS
of_IN
transcription_NN
-LRB-_-LRB-
STAT_NN
-RRB-_-RRB-
in_IN
cancer_NN
patients_NNS
'_POS
lymphocytes_NNS
before_IN
and_CC
after_IN
IL-2_NN
immunotherapy_NN
,_,
as_IN
assessed_VBN
by_IN
a_DT
gel-shift_JJ
assay_NN
._.

An_DT
in_FW
vitro_FW
surrogate_NN
of_IN
IL-2_NN
immunotherapy_NN
is_VBZ
the_DT
incubation_NN
of_IN
fresh_JJ
peripheral_JJ
blood_NN
mononuclear_JJ
cells_NNS
-LRB-_-LRB-
PBMC_NN
-RRB-_-RRB-
from_IN
healthy_JJ
individuals_NNS
in_IN
IL-2_NN
for_IN
several_JJ
days_NNS
,_,
resulting_VBG
in_IN
the_DT
production_NN
of_IN
lymphokine-activated_JJ
killer_NN
-LRB-_-LRB-
LAK_NN
-RRB-_-RRB-
activity_NN
in_IN
these_DT
cultures_NNS
._.

One_CD
purpose_NN
of_IN
this_DT
study_NN
was_VBD
to_TO
describe_VB
the_DT
profile_NN
of_IN
transcription_NN
factor_NN
activation_NN
in_IN
these_DT
different_JJ
populations_NNS
,_,
and_CC
assess_VB
whether_IN
the_DT
patterns_NNS
observed_VBD
correlated_VBD
with_IN
functional_JJ
differences_NNS
in_IN
these_DT
cells_NNS
._.

Prior_JJ
to_TO
in_FW
vivo_FW
IL-2_NN
administration_NN
,_,
the_DT
typical_JJ
binding_NN
pattern_NN
of_IN
transcription_NN
factors_NNS
in_IN
PBMC_NN
from_IN
patients_NNS
resembled_VBD
that_IN
seen_VBN
in_IN
fresh_JJ
PBMC_NN
from_IN
healthy_JJ
individuals_NNS
._.

Over_IN
a_DT
3-week_JJ
course_NN
of_IN
IL-2_NN
therapy_NN
,_,
in_IN
most_JJS
patients_NNS
the_DT
binding_NN
patterns_NNS
of_IN
AP-1_NN
,_,
Sp1_NN
,_,
and_CC
NF-kappaB_NN
proteins_NNS
changed_VBD
to_TO
resemble_VB
those_DT
seen_VBN
in_IN
PBMC_NN
activated_VBN
by_IN
IL-2_NN
in_FW
vitro_FW
._.

However_RB
,_,
the_DT
cells_NNS
obtained_VBN
from_IN
IL-2-treated_JJ
patients_NNS
did_VBD
not_RB
have_VB
low-level_JJ
constitutive_JJ
expression_NN
of_IN
STAT_NN
binding_NN
factors_NNS
as_IN
did_VBD
LAK_NN
cells_NNS
._.

When_WRB
these_DT
patient_NN
cells_NNS
were_VBD
further_RB
stimulated_VBN
by_IN
IL-2_NN
in_FW
vitro_FW
,_,
additional_JJ
differences_NNS
in_IN
STAT_NN
induction_NN
patterns_NNS
were_VBD
noted_VBN
._.

These_DT
data_NNS
provide_VBP
further_JJ
information_NN
on_IN
the_DT
molecular_JJ
events_NNS
occurring_VBG
in_IN
immune_JJ
cells_NNS
generated_VBN
through_IN
in_FW
vivo_FW
and_CC
in_FW
vitro_FW
administration_NN
of_IN
IL-2_NN
,_,
and_CC
further_RB
document_VBP
that_IN
there_EX
is_VBZ
not_RB
a_DT
precise_JJ
congruence_NN
between_IN
PBMC_NN
activated_VBN
in_FW
vivo_FW
and_CC
in_FW
vitro_FW
by_IN
IL-2_NN
._.

